Evofem Biosciences, Inc.
- Close
- Nov 18, 2025
- Market cap
- $1.27M
- 126.69M shares
- Filings
- 804
Q3 2026+4.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q2 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−22.0% FY25 yoy
- $1.27M
- —
- 0.1×
- —
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 18, 2025 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $20,183,000 | reported | |
| FY 2024 | 2024-12-31 | $19,363,000 | reported | |
| FY 2023 | 2023-12-31 | $18,218,000 | reported | |
| FY 2022 | 2022-12-31 | $16,837,000 | reported | |
| FY 2021 | 2021-12-31 | $8,244,000 | reported | |
| FY 2020 | 2020-12-31 | $446,000 | reported | |
| FY 2019 | 2019-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2022 | — | $18.00K | $18.00K | — | 215.96M sh | +28.7% | — |
| FY2021 | — | $0.00 | $0.00 | — | 167.78M sh | +101.9% | — |
| FY2018 | $200.00K | — | $200.00K | — | 28.16M sh | +58.5% | — |
| FY2017 | $200.00K | — | $200.00K | — | 17.76M sh | +28.4% | — |
Pharmaceutical preparations
Evofem Biosciences, Inc. is the 154th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
TRDAEntrada Therapeutics, Inc.$25.4M87.9%565.5%$203.2MALMSAlumis Inc.$24.1M—1,011.7%$796.5MNAMSNewAmsterdam Pharma Co N.V.$22.5M50.6%905.7%$2.4BCASIFCASI Pharmaceuticals, Inc.$20.7M27.4%232.0%$3.1MSCYXScynexis Inc$20.6M449.9%41.8%$32.9M
EVFMEvofem Biosciences, Inc. (this company)$20.2M4.2%1.9%$1.3M
SLGLSol-Gel Technologies Ltd.$19.4M68.0%31.6%$156.0MZYBTZhengye Biotechnology Holding Ltd$16.6M34.8%60.0%$71.6MQUREuniQure N.V.$16.1M40.6%1,236.0%$1.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Evofem Biosciences, Inc. · CIK 1618835 · Engraved from SEC EDGAR